Therapeutic innovations in breast cancer
- PMID: 31151842
- DOI: 10.1016/j.lpm.2019.04.005
Therapeutic innovations in breast cancer
Abstract
Managing endocrine resistance and resistance to endocrine therapy for ER+ HER2- breast cancer with the CDK 4/6 inhibitors in the metastatic setting. New antibodies drug conjugates for HER2+ and TNBC. Targeting DNA damage and synthetic lethality strategies with PARP inhibitors for breast cancer patients harboring BRCA mutation. Immunotherapies in 1st line metastatic setting of TNBC.
Copyright © 2019. Published by Elsevier Masson SAS.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous